Inflammatory Markers, Lobar Pneumonia, Pediatrics, Satisfaction
Conditions
Brief summary
Integrated nursing and medical management significantly improves clinical symptoms and pulmonary function in children with lobar pneumonia, shortens hospitalization duration, reduces complication rates, and enhances caregiver satisfaction. These findings support its broad clinical applicability and value.
Detailed description
This study aims to evaluate the clinical efficacy of integrated nursing and medical management in the treatment of pediatric lobar pneumonia. Specifically, it assesses its impact on symptom relief, pulmonary function recovery, inflammatory response control, duration of hospitalization, and caregiver satisfaction. Fifty pediatric patients diagnosed with lobar pneumonia and admitted to our hospital between January and December 2023 were selected and randomly assigned to either the observation group or the control group (n = 25 each) using a random number table. The control group received routine nursing care, while the observation group was additionally managed with an integrated nursing and medical approach. The two groups were compared in terms of duration of fever, cough, pulmonary rales, antibiotic treatment, length of hospital stay, pulmonary function parameters (FEV₁, FVC, FEV₁/FVC), inflammatory markers (CRP, WBC, PCT, LDH), overall treatment efficacy, caregiver satisfaction, and incidence of adverse events.
Interventions
OTHERobservation group
the observation group was additionally managed with an integrated nursing and medical approach.
OTHERcontrol group
The control group received routine nursing care
Sponsors
Children's Hospital of Hebei Province
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* (1) Met the diagnostic criteria for lobar pneumonia, presenting with symptoms such as fever, cough, and pulmonary rales, and confirmed by laboratory tests and chest X-ray; * (2) Aged between 1 and 12 years; * (3) Informed consent was obtained from the child's legal guardians.
Exclusion criteria
* (1)Presence of other concurrent respiratory diseases; * (2) Congenital or acquired airway malformations, or airway foreign bodies; * (3) Impaired hepatic or renal function; * (4) Presence of other systemic diseases; * (5) Cognitive impairment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Clinical Resolution of Symptoms | From admission until discharge (up to 14 days). | Duration (in days) from hospital admission until resolution of three key symptoms: fever (axillary temperature \<37.3°C for 24h), cough (absence of cough for 48h), and pulmonary rales (absence on auscultation). Assessed daily by blinded clinicians. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in Inflammatory Markers (CRP, PCT, WBC, LDH) | Baseline (T0) and discharge (T1; up to 14 days). | Percent reduction in serum CRP (mg/L), PCT (ng/mL), WBC (×10⁹/L), and LDH (U/L) levels from admission to discharge. |
| Change in Pulmonary Function (FEV₁, FVC, FEV₁/FVC) | Baseline (T0) and discharge (T1; up to 14 days). | Absolute change in spirometry-measured FEV₁ (L), FVC (L), and FEV₁/FVC ratio (%) from admission to discharge. Assessed using standardized spirometry protocols. |
| Length of Hospital Stay | Up to 14 days. | Total days from admission to discharge, documented from electronic health records. |
| Parental Satisfaction Rate | At discharge (T1; up to 14 days). | Proportion of caregivers reporting very satisfied or satisfied on a 4-point Likert scale (very satisfied/satisfied/neutral/dissatisfied) at discharge. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adherence to Rehabilitation Protocols | Daily during hospitalization (up to 14 days). | Compliance with respiratory exercises (e.g., % of scheduled postural drainage sessions completed), tracked via nursing logs. |
| Antibiotic Usage Duration | From admission to discontinuation (up to 14 days). | Total days of intravenous/oral antibiotic therapy, recorded from medication logs. |
| Incidence of Complications | From admission to discharge (up to 14 days). | Proportion of patients experiencing adverse events (e.g., hemoptysis, pneumothorax, bronchospasm) during hospitalization, verified by imaging/lab reports. |
Countries
China
Outcome results
None listed